Comprehensive Genomic Profiling (CGP) of circulating tumor DNA (ctDNA) from blood liquid biopsy provides important results to inform subsequent therapy selection.
In this video interview, Dr. Atocha Romero, Director of the Liquid Biopsy Laboratory of the Medical Oncology Department at the Hospital Universitario Puerta de Hierro in Madrid, Spain, shares her perspective on the value of CGP on ctDNA and explains how her team used liquid biopsy-based comprehensive biomarker testing for lung cancer patients in NADIM II clinical trials.
In particular, the interview addresses these questions:
Why using liquid biopsy?
Which patients can be selected for liquid biopsy?
What is the value of CGP of ctDNA?
What advantages does this diagnostic test approach bring to patients?
Watch video to learn more how comprehensive genomic profiling of ctDNA from liquid biopsy can improve the prognosis and management of cancer patients, by providing insights into tumor progression and response to immunotherapy-based treatments.
#CGP #liquidbiopsy #ctDNA
Subscribe to the Illumina video channel [ Ссылка ]
A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.
View customer spotlight videos
[ Ссылка ]
View Illumina webinars
[ Ссылка ]
View Illumina support videos
[ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]...
Instagram: [ Ссылка ]
Twitter: [ Ссылка ]
